-
2
-
-
0038636398
-
Vitamin D: more than a "bone-a-fide" hormone
-
Sutton AL, MacDonald PN. Vitamin D: more than a "bone-a-fide" hormone. Mol Endocrinol 2003; 17: 777-91.
-
(2003)
Mol Endocrinol
, vol.17
, pp. 777-791
-
-
Sutton, A.L.1
MacDonald, P.N.2
-
3
-
-
0037224484
-
Nongenomic actions of steroid hormones
-
Losel R, Wehling M. Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol 2003; 4: 46-56.
-
(2003)
Nat Rev Mol Cell Biol
, vol.4
, pp. 46-56
-
-
Losel, R.1
Wehling, M.2
-
4
-
-
0345874610
-
Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model
-
Norman AW, Mizwicki MT, Norman DP. Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nat Rev Drug Discov 2004; 3: 27-41.
-
(2004)
Nat Rev Drug Discov
, vol.3
, pp. 27-41
-
-
Norman, A.W.1
Mizwicki, M.T.2
Norman, D.P.3
-
6
-
-
33645740073
-
Prospective study of predictors of vitamin D status and cancer incidence and mortality in men
-
Giovannucci E, Liu Y, Rimm EB, et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 2006; 98: 451-9.
-
(2006)
J Natl Cancer Inst
, vol.98
, pp. 451-459
-
-
Giovannucci, E.1
Liu, Y.2
Rimm, E.B.3
-
8
-
-
58949095024
-
Vitamin D and cancer incidence in the Harvard cohorts
-
Giovannucci E. Vitamin D and cancer incidence in the Harvard cohorts. Ann Epidemiol 2009; 19: 84-8.
-
(2009)
Ann Epidemiol
, vol.19
, pp. 84-88
-
-
Giovannucci, E.1
-
9
-
-
46449125088
-
Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer
-
Ng K, Meyerhardt JA, Wu K, et al. Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer. J Clin Oncol 2008; 26: 2984-91.
-
(2008)
J Clin Oncol
, vol.26
, pp. 2984-2991
-
-
Ng, K.1
Meyerhardt, J.A.2
Wu, K.3
-
10
-
-
55849118096
-
Vitamin D status and the risk of lung cancer: a cohort study in Finland
-
Kilkkinen A, Knekt P, Heliovaara M, et al. Vitamin D status and the risk of lung cancer: a cohort study in Finland. Cancer Epidemiol Biomarkers Prev 2008; 17: 3274-8.
-
(2008)
Cancer Epidemiol Biomarkers Prev
, vol.17
, pp. 3274-3278
-
-
Kilkkinen, A.1
Knekt, P.2
Heliovaara, M.3
-
11
-
-
0028879760
-
Cisplatin and DNA repair in cancer chemotherapy
-
Zamble DB, Lippard SJ. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci 1995; 20: 435-9.
-
(1995)
Trends Biochem Sci
, vol.20
, pp. 435-439
-
-
Zamble, D.B.1
Lippard, S.J.2
-
13
-
-
0025851237
-
Combined effects of 1,25-dihydroxyvitamin D3 and platinum drugs on the growth of MCF-7 cells
-
Cho YL, Christensen C, Saunders DE, et al. Combined effects of 1,25-dihydroxyvitamin D3 and platinum drugs on the growth of MCF-7 cells. Cancer Res 1991; 51: 2848-53.
-
(1991)
Cancer Res
, vol.51
, pp. 2848-2853
-
-
Cho, Y.L.1
Christensen, C.2
Saunders, D.E.3
-
14
-
-
0032587095
-
1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines
-
Moffatt KA, Johannes WU, Miller GJ. 1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin Cancer Res 1999; 5: 695-703.
-
(1999)
Clin Cancer Res
, vol.5
, pp. 695-703
-
-
Moffatt, K.A.1
Johannes, W.U.2
Miller, G.J.3
-
15
-
-
68049092791
-
Use of combination therapy with cisplatin and calcitriol in the treatment of Y-79 human retinoblastoma xenograft model
-
Kulkarni AD, van Ginkel PR, Darjatmoko SR, Lindstrom MJ, Albert DM. Use of combination therapy with cisplatin and calcitriol in the treatment of Y-79 human retinoblastoma xenograft model. Br J Ophthalmol 2009; 93: 1105-8.
-
(2009)
Br J Ophthalmol
, vol.93
, pp. 1105-1108
-
-
Kulkarni, A.D.1
van Ginkel, P.R.2
Darjatmoko, S.R.3
Lindstrom, M.J.4
Albert, D.M.5
-
16
-
-
49749146435
-
In vitro and in vivo evaluation of combined calcitriol and cisplatin in dogs with spontaneously occurring tumors
-
Rassnick KM, Muindi JR, Johnson CS, et al. In vitro and in vivo evaluation of combined calcitriol and cisplatin in dogs with spontaneously occurring tumors. Cancer Chemother Pharmacol 2008; 62: 881-91.
-
(2008)
Cancer Chemother Pharmacol
, vol.62
, pp. 881-891
-
-
Rassnick, K.M.1
Muindi, J.R.2
Johnson, C.S.3
-
17
-
-
0030880944
-
Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system
-
Light BW, Yu WD, McElwain MC, Russell DM, Trump DL, Johnson CS. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res 1997; 57: 3759-64.
-
(1997)
Cancer Res
, vol.57
, pp. 3759-3764
-
-
Light, B.W.1
Yu, W.D.2
McElwain, M.C.3
Russell, D.M.4
Trump, D.L.5
Johnson, C.S.6
-
18
-
-
0036689119
-
Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression
-
Hershberger PA, McGuire TF, Yu WD, et al. Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression. Mol Cancer Ther 2002; 1: 821-9.
-
(2002)
Mol Cancer Ther
, vol.1
, pp. 821-829
-
-
Hershberger, P.A.1
McGuire, T.F.2
Yu, W.D.3
-
19
-
-
54049152433
-
1alpha,25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model
-
Ma Y, Yu WD, Hershberger PA, et al. 1alpha,25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model. Mol Cancer Ther 2008; 7: 3047-55.
-
(2008)
Mol Cancer Ther
, vol.7
, pp. 3047-3055
-
-
Ma, Y.1
Yu, W.D.2
Hershberger, P.A.3
-
20
-
-
0033557922
-
1,25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage
-
Ravid A, Rocker D, Machlenkin A, et al. 1, 25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage. Cancer Res 1999; 59: 862-7.
-
(1999)
Cancer Res
, vol.59
, pp. 862-867
-
-
Ravid, A.1
Rocker, D.2
Machlenkin, A.3
-
21
-
-
0027988168
-
Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogues and tamoxifen
-
Vink-van Wijngaarden T, Pols HA, Buurman CJ, et al. Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogues and tamoxifen. Cancer Res 1994; 54: 5711-7.
-
(1994)
Cancer Res
, vol.54
, pp. 5711-5717
-
-
Vink-van Wijngaarden, T.1
Pols, H.A.2
Buurman, C.J.3
-
22
-
-
0027276092
-
Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen
-
Abe-Hashimoto J, Kikuchi T, Matsumoto T, Nishii Y, Ogata E, Ikeda K. Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen. Cancer Res 1993; 53: 2534-7.
-
(1993)
Cancer Res
, vol.53
, pp. 2534-2537
-
-
Abe-Hashimoto, J.1
Kikuchi, T.2
Matsumoto, T.3
Nishii, Y.4
Ogata, E.5
Ikeda, K.6
-
23
-
-
73449112996
-
Vitamin D mediates its action in human colon carcinoma cells in a calcium-sensing receptor-dependent manner: downregulates malignant cell behavior and the expression of thymidylate synthase and survivin and promotes cellular sensitivity to 5-FU
-
Liu G, Hu X, Chakrabarty S. Vitamin D mediates its action in human colon carcinoma cells in a calcium-sensing receptor-dependent manner: downregulates malignant cell behavior and the expression of thymidylate synthase and survivin and promotes cellular sensitivity to 5-FU. Int J Cancer 2010; 126: 631-9.
-
(2010)
Int J Cancer
, vol.126
, pp. 631-639
-
-
Liu, G.1
Hu, X.2
Chakrabarty, S.3
-
24
-
-
0025935613
-
Potentiation of 1-beta-D-arabinofuranosylcytosine cytotoxicity to HL-60 cells by 1,25-dihydroxyvitamin D3 correlates with reduced rate of maturation of DNA replication intermediates
-
Studzinski GP, Reddy KB, Hill HZ, Bhandal AK. Potentiation of 1-beta-D-arabinofuranosylcytosine cytotoxicity to HL-60 cells by 1,25-dihydroxyvitamin D3 correlates with reduced rate of maturation of DNA replication intermediates. Cancer Res 1991; 51: 3451-5.
-
(1991)
Cancer Res
, vol.51
, pp. 3451-3455
-
-
Studzinski, G.P.1
Reddy, K.B.2
Hill, H.Z.3
Bhandal, A.K.4
-
25
-
-
0026697840
-
Treatment of acute myeloid leukemia in the elderly with low-dose cytarabine, hydroxyurea, and calcitriol
-
Slapak CA, Desforges JF, Fogaren T, Miller KB. Treatment of acute myeloid leukemia in the elderly with low-dose cytarabine, hydroxyurea, and calcitriol. Am J Hematol 1992; 41: 178-83.
-
(1992)
Am J Hematol
, vol.41
, pp. 178-183
-
-
Slapak, C.A.1
Desforges, J.F.2
Fogaren, T.3
Miller, K.B.4
-
26
-
-
2542466836
-
Differentiating agents + low-dose chemotherapy in the management of old/poor prognosis patients with acute myeloid leukemia or myelodysplastic syndrome
-
Ferrero D, Campa E, Dellacasa C, Campana S, Foli C, Boccadoro M. Differentiating agents + low-dose chemotherapy in the management of old/poor prognosis patients with acute myeloid leukemia or myelodysplastic syndrome. Haematologica 2004; 89: 619-20.
-
(2004)
Haematologica
, vol.89
, pp. 619-620
-
-
Ferrero, D.1
Campa, E.2
Dellacasa, C.3
Campana, S.4
Foli, C.5
Boccadoro, M.6
-
27
-
-
0033990705
-
Myeloid and monocytoid leukemia cells have different sensitivity to differentiation-inducing activity of deoxyadenosine analogs
-
Niitsu N, Umeda M, Honma Y. Myeloid and monocytoid leukemia cells have different sensitivity to differentiation-inducing activity of deoxyadenosine analogs. Leuk Res 2000; 24: 1-9.
-
(2000)
Leuk Res
, vol.24
, pp. 1-9
-
-
Niitsu, N.1
Umeda, M.2
Honma, Y.3
-
28
-
-
0031985235
-
Growth inhibition and differentiation induction in human monoblastic leukaemia cells by 1alpha-hydroxyvitamin D derivatives and their enhancement by combination with hydroxyurea
-
Makishima M, Okabe-Kado J, Honma Y. Growth inhibition and differentiation induction in human monoblastic leukaemia cells by 1alpha-hydroxyvitamin D derivatives and their enhancement by combination with hydroxyurea. Br J Cancer 1998; 77: 33-9.
-
(1998)
Br J Cancer
, vol.77
, pp. 33-39
-
-
Makishima, M.1
Okabe-Kado, J.2
Honma, Y.3
-
29
-
-
33846581566
-
Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer
-
Sternberg CN, Donat SM, Bellmunt J, et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology 2007; 69: 62-79.
-
(2007)
Urology
, vol.69
, pp. 62-79
-
-
Sternberg, C.N.1
Donat, S.M.2
Bellmunt, J.3
-
31
-
-
77954277193
-
1,25D(3) Enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models
-
Ma Y, Yu WD, Trump DL, Johnson CS. 1,25D(3) Enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models. Cancer 2010; 116: 3294-303.
-
(2010)
Cancer
, vol.116
, pp. 3294-3303
-
-
Ma, Y.1
Yu, W.D.2
Trump, D.L.3
Johnson, C.S.4
-
32
-
-
77956831569
-
Calcitriol enhances gemcitabine anti-tumor activity in vitro and in vivo by promoting apoptosis in a human pancreatic carcinoma model system
-
in press
-
Yu WD, Ma Y, Flynn G, et al. Calcitriol enhances gemcitabine anti-tumor activity in vitro and in vivo by promoting apoptosis in a human pancreatic carcinoma model system. Cell Cycle 2010; in press.
-
Cell Cycle 2010
-
-
Yu, W.D.1
Ma, Y.2
Flynn, G.3
-
33
-
-
0034896572
-
Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis
-
Hershberger PA, Yu WD, Modzelewski RA, Rueger RM, Johnson CS, Trump DL. Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res 2001; 7: 1043-51.
-
(2001)
Clin Cancer Res
, vol.7
, pp. 1043-1051
-
-
Hershberger, P.A.1
Yu, W.D.2
Modzelewski, R.A.3
Rueger, R.M.4
Johnson, C.S.5
Trump, D.L.6
-
34
-
-
0034086039
-
1,25-Dihydroxyvitamin D3 and all-trans-retinoic acid sensitize breast cancer cells to chemotherapy-induced cell death
-
Wang Q, Yang W, Uytingco MS, Christakos S, Wieder R. 1,25-Dihydroxyvitamin D3 and all-trans-retinoic acid sensitize breast cancer cells to chemotherapy-induced cell death. Cancer Res 2000; 60: 2040-8.
-
(2000)
Cancer Res
, vol.60
, pp. 2040-2048
-
-
Wang, Q.1
Yang, W.2
Uytingco, M.S.3
Christakos, S.4
Wieder, R.5
-
35
-
-
33845599555
-
Docetaxel-induced growth inhibition and apoptosis in androgen independent prostate cancer cells are enhanced by 1alpha, 25-dihydroxyvitamin D3
-
Ting HJ, Hsu J, Bao BY, Lee YF. Docetaxel-induced growth inhibition and apoptosis in androgen independent prostate cancer cells are enhanced by 1alpha,25-dihydroxyvitamin D3. Cancer Lett 2007; 247: 122-9.
-
(2007)
Cancer Lett
, vol.247
, pp. 122-129
-
-
Ting, H.J.1
Hsu, J.2
Bao, B.Y.3
Lee, Y.F.4
-
36
-
-
0032928303
-
Combined effect of vitamin D3 analogs and paclitaxel on the growth of MCF-7 breast cancer cells in vivo
-
Koshizuka K, Koike M, Asou H, et al. Combined effect of vitamin D3 analogs and paclitaxel on the growth of MCF-7 breast cancer cells in vivo. Breast Cancer Res Treat 1999; 53: 113-20.
-
(1999)
Breast Cancer Res Treat
, vol.53
, pp. 113-120
-
-
Koshizuka, K.1
Koike, M.2
Asou, H.3
-
37
-
-
0034744476
-
The vitamin D3 analog, ILX-23-7553, enhances the response to adriamycin and irradiation in MCF-7 breast tumor cells
-
Chaudhry M, Sundaram S, Gennings C, Carter H, Gewirtz DA. The vitamin D3 analog, ILX-23-7553, enhances the response to adriamycin and irradiation in MCF-7 breast tumor cells. Cancer Chemother Pharmacol 2001; 47: 429-36.
-
(2001)
Cancer Chemother Pharmacol
, vol.47
, pp. 429-436
-
-
Chaudhry, M.1
Sundaram, S.2
Gennings, C.3
Carter, H.4
Gewirtz, D.A.5
-
38
-
-
1842868727
-
Combination treatment with 1alpha,25-dihydroxyvitamin D3 and 9-cis-retinoic acid directly inhibits human telomerase reverse transcriptase transcription in prostate cancer cells
-
Ikeda N, Uemura H, Ishiguro H, et al. Combination treatment with 1alpha,25-dihydroxyvitamin D3 and 9-cis-retinoic acid directly inhibits human telomerase reverse transcriptase transcription in prostate cancer cells. Mol Cancer Ther 2003; 2: 739-46.
-
(2003)
Mol Cancer Ther
, vol.2
, pp. 739-746
-
-
Ikeda, N.1
Uemura, H.2
Ishiguro, H.3
-
39
-
-
0031036661
-
Synergistic decrease of clonal proliferation, induction of differentiation, and apoptosis of acute promyelocytic leukemia cells after combined treatment with novel 20-epi vitamin D3 analogs and 9-cis retinoic acid
-
Elstner E, Linker-Israeli M, Le J, et al. Synergistic decrease of clonal proliferation, induction of differentiation, and apoptosis of acute promyelocytic leukemia cells after combined treatment with novel 20-epi vitamin D3 analogs and 9-cis retinoic acid. J Clin Invest 1997; 99: 349-60.
-
(1997)
J Clin Invest
, vol.99
, pp. 349-360
-
-
Elstner, E.1
Linker-Israeli, M.2
Le, J.3
-
40
-
-
8044226035
-
Combination of a potent 20-epi-vitamin D3 analogue (KH 1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells
-
Elstner E, Linker-Israeli M, Umiel T, et al. Combination of a potent 20-epi-vitamin D3 analogue (KH 1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells. Cancer Res 1996; 56: 3570-6.
-
(1996)
Cancer Res
, vol.56
, pp. 3570-3576
-
-
Elstner, E.1
Linker-Israeli, M.2
Umiel, T.3
-
41
-
-
0035810045
-
Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A
-
Rashid SF, Moore JS, Walker E, et al. Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. Oncogene 2001; 20: 1860-72.
-
(2001)
Oncogene
, vol.20
, pp. 1860-1872
-
-
Rashid, S.F.1
Moore, J.S.2
Walker, E.3
-
42
-
-
0043236062
-
1alpha,25-dihydroxyvitamin D(3) (calcitriol) and its analogue, 19-nor-1alpha,25(OH)(2)D(2), potentiate the effects of ionising radiation on human prostate cancer cells
-
Dunlap N, Schwartz GG, Eads D, et al. 1alpha,25-dihydroxyvitamin D(3) (calcitriol) and its analogue, 19-nor-1alpha,25(OH)(2)D(2), potentiate the effects of ionising radiation on human prostate cancer cells. Br J Cancer 2003; 89: 746-53.
-
(2003)
Br J Cancer
, vol.89
, pp. 746-753
-
-
Dunlap, N.1
Schwartz, G.G.2
Eads, D.3
-
43
-
-
0038276041
-
The combination of a potent vitamin D3 analog, EB 1089, with ionizing radiation reduces tumor growth and induces apoptosis of MCF-7 breast tumor xenografts in nude mice
-
Sundaram S, Sea A, Feldman S, et al. The combination of a potent vitamin D3 analog, EB 1089, with ionizing radiation reduces tumor growth and induces apoptosis of MCF-7 breast tumor xenografts in nude mice. Clin Cancer Res 2003; 9: 2350-6.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 2350-2356
-
-
Sundaram, S.1
Sea, A.2
Feldman, S.3
-
44
-
-
67650351201
-
Inhibition of RelB by 1,25-dihydroxyvitamin D3 promotes sensitivity of breast cancer cells to radiation
-
Mineva ND, Wang X, Yang S, et al. Inhibition of RelB by 1,25-dihydroxyvitamin D3 promotes sensitivity of breast cancer cells to radiation. J Cell Physiol 2009; 220: 593-9.
-
(2009)
J Cell Physiol
, vol.220
, pp. 593-599
-
-
Mineva, N.D.1
Wang, X.2
Yang, S.3
-
45
-
-
73349127819
-
Calcitriol treatment improves methyl aminolaevulinate-based photodynamic therapy in human squamous cell carcinoma A431 cells
-
Cicarma E, Tuorkey M, Juzeniene A, Ma LW, Moan J. Calcitriol treatment improves methyl aminolaevulinate-based photodynamic therapy in human squamous cell carcinoma A431 cells. Br J Dermatol 2009; 161: 413-8.
-
(2009)
Br J Dermatol
, vol.161
, pp. 413-418
-
-
Cicarma, E.1
Tuorkey, M.2
Juzeniene, A.3
Ma, L.W.4
Moan, J.5
-
46
-
-
42449162971
-
Induction of differentiation of human leukemia cells by combinations of COX inhibitors and 1,25-dihydroxyvitamin D3 involves Raf1 but not Erk 1/2 signaling
-
Jamshidi F, Zhang J, Harrison JS, Wang X, Studzinski GP. Induction of differentiation of human leukemia cells by combinations of COX inhibitors and 1,25-dihydroxyvitamin D3 involves Raf1 but not Erk 1/2 signaling. Cell Cycle 2008; 7: 917-24.
-
(2008)
Cell Cycle
, vol.7
, pp. 917-924
-
-
Jamshidi, F.1
Zhang, J.2
Harrison, J.S.3
Wang, X.4
Studzinski, G.P.5
-
47
-
-
23344449304
-
The combined treatment of 1,25-dihydroxyvitamin D3 and a non-steroid anti-inflammatory drug is highly effective in suppressing prostate cancer cell line (LNCaP) growth
-
Gavrilov V, Steiner M, Shany S. The combined treatment of 1,25-dihydroxyvitamin D3 and a non-steroid anti-inflammatory drug is highly effective in suppressing prostate cancer cell line (LNCaP) growth. Anticancer Res 2005; 25: 3425-9.
-
(2005)
Anticancer Res
, vol.25
, pp. 3425-3429
-
-
Gavrilov, V.1
Steiner, M.2
Shany, S.3
-
48
-
-
0036054309
-
Combination of 22-oxa-1,25-dihydroxyvitamin D(3), a vitamin D(3) derivative, with vitamin K(2) (VK2) synergistically enhances cell differentiation but suppresses VK2-inducing apoptosis in HL-60 cells
-
Funato K, Miyazawa K, Yaguchi M, Gotoh A, Ohyashiki K. Combination of 22-oxa-1,25-dihydroxyvitamin D(3), a vitamin D(3) derivative, with vitamin K(2) (VK2) synergistically enhances cell differentiation but suppresses VK2-inducing apoptosis in HL-60 cells. Leukemia 2002; 16: 1519-27.
-
(2002)
Leukemia
, vol.16
, pp. 1519-1527
-
-
Funato, K.1
Miyazawa, K.2
Yaguchi, M.3
Gotoh, A.4
Ohyashiki, K.5
-
49
-
-
0037444401
-
Carnosic acid potentiates the antioxidant and prodifferentiation effects of 1alpha,25-dihydroxyvitamin D3 in leukemia cells but does not promote elevation of basal levels of intracellular calcium
-
Danilenko M, Wang Q, Wang X, Levy J, Sharoni Y, Studzinski GP. Carnosic acid potentiates the antioxidant and prodifferentiation effects of 1alpha,25-dihydroxyvitamin D3 in leukemia cells but does not promote elevation of basal levels of intracellular calcium. Cancer Res 2003; 63: 1325-32.
-
(2003)
Cancer Res
, vol.63
, pp. 1325-1332
-
-
Danilenko, M.1
Wang, Q.2
Wang, X.3
Levy, J.4
Sharoni, Y.5
Studzinski, G.P.6
-
50
-
-
1242316960
-
1alpha,25-dihydroxyvitamin D3 and bryostatin-1 synergize to induce monocytic differentiation of NB4 acute promyelocytic leukemia cells by modulating cell cycle progression
-
Clark CS, Konyer JE, Meckling KA. 1alpha,25-dihydroxyvitamin D3 and bryostatin-1 synergize to induce monocytic differentiation of NB4 acute promyelocytic leukemia cells by modulating cell cycle progression. Exp Cell Res 2004; 294: 301-11.
-
(2004)
Exp Cell Res
, vol.294
, pp. 301-311
-
-
Clark, C.S.1
Konyer, J.E.2
Meckling, K.A.3
-
51
-
-
0032588622
-
Bryostatin-1 and 1alpha,25-dihydroxyvitamin D3 synergistically stimulate the differentiation of NB4 acute promyelocytic leukemia cells
-
Song XD, Norman AW. Bryostatin-1 and 1alpha,25-dihydroxyvitamin D3 synergistically stimulate the differentiation of NB4 acute promyelocytic leukemia cells. Leukemia 1999; 13: 275-81.
-
(1999)
Leukemia
, vol.13
, pp. 275-281
-
-
Song, X.D.1
Norman, A.W.2
-
52
-
-
77951046942
-
Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia
-
Callens C, Coulon S, Naudin J, et al. Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med 2010; 207: 731-50.
-
(2010)
J Exp Med
, vol.207
, pp. 731-750
-
-
Callens, C.1
Coulon, S.2
Naudin, J.3
-
53
-
-
0032554056
-
Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone
-
Yu WD, McElwain MC, Modzelewski RA, et al. Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone. J Natl Cancer Inst 1998; 90: 134-41.
-
(1998)
J Natl Cancer Inst
, vol.90
, pp. 134-141
-
-
Yu, W.D.1
McElwain, M.C.2
Modzelewski, R.A.3
-
54
-
-
0035542953
-
Combination of 1alpha,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling
-
Bernardi RJ, Trump DL, Yu WD, McGuire TF, Hershberger PA, Johnson CS. Combination of 1alpha,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling. Clin Cancer Res 2001; 7: 4164-73.
-
(2001)
Clin Cancer Res
, vol.7
, pp. 4164-4173
-
-
Bernardi, R.J.1
Trump, D.L.2
Yu, W.D.3
McGuire, T.F.4
Hershberger, P.A.5
Johnson, C.S.6
-
56
-
-
0036784267
-
Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells
-
Peehl DM, Seto E, Hsu JY, Feldman D. Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells. J Urol 2002; 168: 1583-8.
-
(2002)
J Urol
, vol.168
, pp. 1583-1588
-
-
Peehl, D.M.1
Seto, E.2
Hsu, J.Y.3
Feldman, D.4
-
57
-
-
0033324493
-
Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity
-
Ly LH, Zhao XY, Holloway L, Feldman D. Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology 1999; 140: 2071-6.
-
(1999)
Endocrinology
, vol.140
, pp. 2071-2076
-
-
Ly, L.H.1
Zhao, X.Y.2
Holloway, L.3
Feldman, D.4
-
58
-
-
58849087664
-
RRR-alpha-vitamin E succinate potentiates the antitumor effect of calcitriol in prostate cancer without overt side effects
-
Yin Y, Ni J, Chen M, Guo Y, Yeh S. RRR-alpha-vitamin E succinate potentiates the antitumor effect of calcitriol in prostate cancer without overt side effects. Clin Cancer Res 2009; 15: 190-200.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 190-200
-
-
Yin, Y.1
Ni, J.2
Chen, M.3
Guo, Y.4
Yeh, S.5
-
59
-
-
61349100067
-
Antiproliferative action of menadione and 1,25(OH)2D3 on breast cancer cells
-
Marchionatti AM, Picotto G, Narvaez CJ, Welsh J, Tolosa de Talamoni NG. Antiproliferative action of menadione and 1,25(OH)2D3 on breast cancer cells. J Steroid Biochem Mol Biol 2009; 113: 227-32.
-
(2009)
J Steroid Biochem Mol Biol
, vol.113
, pp. 227-232
-
-
Marchionatti, A.M.1
Picotto, G.2
Narvaez, C.J.3
Welsh, J.4
Tolosa de Talamoni, N.G.5
-
60
-
-
1542720378
-
Vitamin D receptor and p21/WAF1 are targets of genistein and 1,25-dihydroxyvitamin D3 in human prostate cancer cells
-
Rao A, Coan A, Welsh JE, Barclay WW, Koumenis C, Cramer SD. Vitamin D receptor and p21/WAF1 are targets of genistein and 1,25-dihydroxyvitamin D3 in human prostate cancer cells. Cancer Res 2004; 64: 2143-7.
-
(2004)
Cancer Res
, vol.64
, pp. 2143-2147
-
-
Rao, A.1
Coan, A.2
Welsh, J.E.3
Barclay, W.W.4
Koumenis, C.5
Cramer, S.D.6
-
61
-
-
24344448674
-
Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: role of the direct inhibition of CYP24 enzyme activity
-
Swami S, Krishnan AV, Peehl DM, Feldman D. Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: role of the direct inhibition of CYP24 enzyme activity. Mol Cell Endocrinol 2005; 241: 49-61.
-
(2005)
Mol Cell Endocrinol
, vol.241
, pp. 49-61
-
-
Swami, S.1
Krishnan, A.V.2
Peehl, D.M.3
Feldman, D.4
-
62
-
-
67049156854
-
Enhancement of 1,25-dihydroxyvitamin D3- and all-trans retinoic acid-induced HL-60 leukemia cell differentiation by Panax ginseng
-
Kim SH, Cho SS, Simkhada JR, et al. Enhancement of 1,25-dihydroxyvitamin D3- and all-trans retinoic acid-induced HL-60 leukemia cell differentiation by Panax ginseng. Biosci Biotechnol Biochem 2009; 73: 1048-53.
-
(2009)
Biosci Biotechnol Biochem
, vol.73
, pp. 1048-1053
-
-
Kim, S.H.1
Cho, S.S.2
Simkhada, J.R.3
-
63
-
-
35148840489
-
S179D prolactin sensitizes human prostate cancer cell s such that physi ol ogi cal concentrati ons of 1,25 dihydroxy vitamin D3 result in growth inhibition and cell death
-
Wu W, Zanello L, Walker AM. S179D prolactin sensitizes human prostate cancer cell s such that physi ol ogi cal concentrati ons of 1, 25 dihydroxy vitamin D3 result in growth inhibition and cell death. Prostate 2007; 67: 1498-506.
-
(2007)
Prostate
, vol.67
, pp. 1498-1506
-
-
Wu, W.1
Zanello, L.2
Walker, A.M.3
-
64
-
-
33846813508
-
Synergism between vitamin D and secreted protein acidic and rich in cysteine-induced apoptosis and growth inhibition results in increased susceptibility of therapy-resistant colorectal cancer cells to chemotherapy
-
Taghizadeh F, Tang MJ, Tai IT. Synergism between vitamin D and secreted protein acidic and rich in cysteine-induced apoptosis and growth inhibition results in increased susceptibility of therapy-resistant colorectal cancer cells to chemotherapy. Mol Cancer Ther 2007; 6: 309-17.
-
(2007)
Mol Cancer Ther
, vol.6
, pp. 309-317
-
-
Taghizadeh, F.1
Tang, M.J.2
Tai, I.T.3
-
66
-
-
77149128673
-
Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy
-
Trump DL, Deeb KK, Johnson CS. Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Cancer J 2010; 16: 1-9.
-
(2010)
Cancer J
, vol.16
, pp. 1-9
-
-
Trump, D.L.1
Deeb, K.K.2
Johnson, C.S.3
-
67
-
-
0030794319
-
Vitamin D: an antiproliferative agent with potential for therapy of squamous cell carcinoma
-
McElwain MC, Modzelewski RA, Yu WD, Russell DM, Johnson CS. Vitamin D: an antiproliferative agent with potential for therapy of squamous cell carcinoma. Am J Otolaryngol 1997; 18: 293-8.
-
(1997)
Am J Otolaryngol
, vol.18
, pp. 293-298
-
-
McElwain, M.C.1
Modzelewski, R.A.2
Yu, W.D.3
Russell, D.M.4
Johnson, C.S.5
-
68
-
-
1642566524
-
Pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses
-
Muindi JR, Modzelewski RA, Peng Y, Trump DL, Johnson CS. Pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses. Oncology 2004; 66: 62-6.
-
(2004)
Oncology
, vol.66
, pp. 62-66
-
-
Muindi, J.R.1
Modzelewski, R.A.2
Peng, Y.3
Trump, D.L.4
Johnson, C.S.5
-
69
-
-
0032978243
-
A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy
-
Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW, Trump DL. A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res 1999; 5: 1339-45.
-
(1999)
Clin Cancer Res
, vol.5
, pp. 1339-1345
-
-
Smith, D.C.1
Johnson, C.S.2
Freeman, C.C.3
Muindi, J.4
Wilson, J.W.5
Trump, D.L.6
-
70
-
-
33947250294
-
A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors
-
Fakih MG, Trump DL, Muindi JR, et al. A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors. Clin Cancer Res 2007; 13: 1216-23.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 1216-1223
-
-
Fakih, M.G.1
Trump, D.L.2
Muindi, J.R.3
-
71
-
-
0035875881
-
A Phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation
-
Beer TM, Munar M, Henner WD. A Phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. Cancer 2001; 91: 2431-9.
-
(2001)
Cancer
, vol.91
, pp. 2431-2439
-
-
Beer, T.M.1
Munar, M.2
Henner, W.D.3
-
72
-
-
0036913420
-
Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel
-
Muindi JR, Peng Y, Potter DM, et al. Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. Clin Pharmacol Ther 2002; 72: 648-59.
-
(2002)
Clin Pharmacol Ther
, vol.72
, pp. 648-659
-
-
Muindi, J.R.1
Peng, Y.2
Potter, D.M.3
-
73
-
-
33847121998
-
Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer
-
Beer TM, Javle MM, Ryan CW, et al. Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. Cancer Chemother Pharmacol 2007; 59: 581-7.
-
(2007)
Cancer Chemother Pharmacol
, vol.59
, pp. 581-587
-
-
Beer, T.M.1
Javle, M.M.2
Ryan, C.W.3
-
74
-
-
27744528525
-
Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer
-
Beer TM, Javle M, Lam GN, Henner WD, Wong A, Trump DL. Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. Clin Cancer Res 2005; 11: 7794-9.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 7794-7799
-
-
Beer, T.M.1
Javle, M.2
Lam, G.N.3
Henner, W.D.4
Wong, A.5
Trump, D.L.6
|